Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease


YILDIZ F., ZENGİN N., Engin H., Güllü I., BARIŞTA İ., Çaglar M., ...More

International Journal of Radiation Oncology Biology Physics, vol.60, no.3, pp.839-846, 2004 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 60 Issue: 3
  • Publication Date: 2004
  • Doi Number: 10.1016/j.ijrobp.2004.04.002
  • Journal Name: International Journal of Radiation Oncology Biology Physics
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.839-846
  • Keywords: Hodgkin's disease, early stage, treatment, INVOLVED-FIELD RADIOTHERAPY, PROGNOSTIC-FACTORS, RANDOMIZED-TRIAL, CHEMOTHERAPY, LYMPHOMA, VINBLASTINE, IRRADIATION, EXPERIENCE, RADIATION, BLEOMYCIN
  • Lokman Hekim University Affiliated: No

Abstract

Purpose To determine the efficacy and toxicity of combined modality treatment (CMT) or radiotherapy (RT) alone in the management of clinical Stage I-IIA adult Hodgkin's disease patients. Methods and materials Forty-seven patients with supradiaphragmatic clinical Stage I-IIA Hodgkin's disease without bulky mediastinal lymphadenopathy were enrolled into this prospective study between September 1997 and February 2002. Patients with very favorable criteria presenting with one or two nonbulky nodal areas involved, an erythrocyte sedimentation rate of <50 mm/h, age <40 years, and either lymphocyte predominant or nodular sclerosing histologic findings were treated by RT alone. Patients missing any of these favorable criteria were classified as the other favorable group and were treated with three courses of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy followed by involved-field RT. The median age was 36 years (range, 19-53 years). Of the 47 patients, 15 were women and 32 were men. Only 3 patients were classified as the most favorable group and treated with mantle RT alone; the remaining 44 were treated with CMT. Results The median follow-up was 51 months (range, 20-74 months). Only 2 patients developed recurrence, both out of the irradiated field, one in the contralateral neck and the other in the abdomen. The 5-year relapse-free and overall survival rate was 95.4% and 97.8%, respectively. Although none of the prognostic factors were statistically significant for relapse-free survival, a trend was noted for the response to chemotherapy (p = 0.06). Only 2 patients developed treatment-related complications. One patient treated with mantle RT alone developed severe ischemic heart disease and one in the CMT arm developed subclinical hypothyroidism. Conclusion Despite the short follow-up, CMT or RT alone tailored according to the clinical prognostic factors were successful in terms of disease control in clinical Stage I-IIA Hodgkin's disease. Longer follow-up is required to make definitive conclusions. © 2004 Elsevier Inc.